Literature DB >> 17594389

The importance of beta-cell management in type 2 diabetes.

E Standl1.   

Abstract

Despite intervention with effective oral glucose-lowering agents, most patients with type 2 diabetes will experience a gradual loss of glycaemic control. Irrespective of underlying levels of insulin resistance, the progressive failure and loss of beta-cells are ultimately responsible for the onset of frank type 2 diabetes. The mechanisms responsible for loss of beta-cell function are likely to be multifactorial, but may involve toxicity because of elevated glucose and/or lipid levels, increased secretory demand because of insulin resistance, amyloid deposition and altered levels of cytokines. Preservation of beta-cell function is now gaining recognition as a critical target in the management of type 2 diabetes. For patients with frank type 2 diabetes, preservation of beta-cell function has the potential to reduce or stabilise the progression of type 2 diabetes and to decrease the need for additional oral glucose-lowering agents and/or insulin therapy. There is a growing body of animal/preclinical evidence for improved and preserved beta-cell function with current glucose-lowering agents, such as the thiazolidinediones, metformin and the glucagon-like peptide-1 analogue, exenatide. Clinical studies incorporating indirect measures of beta-cell function also support a protective effect with some agents. A number of novel therapies that are currently under investigation may also offer beta-cell structural and functional protection, including dipeptidyl peptidase IV inhibitors and cannabinoid receptor type 1 blockers. Emerging evidence from interventional trials suggests that both intensive lifestyle changes and pharmacotherapy can delay or possibly prevent the onset of type 2 diabetes in high-risk individuals. For patients newly diagnosed with type 2 diabetes, early and aggressive intervention strategies that combine maximal glucose-lowering efficacy alongside potential beta-cell preserving properties may provide an opportunity to delay or prevent progression of the disease.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17594389     DOI: 10.1111/j.1742-1241.2007.01360.x

Source DB:  PubMed          Journal:  Int J Clin Pract Suppl        ISSN: 1368-504X


  9 in total

Review 1.  Imaging beta-cell mass and function in situ and in vivo.

Authors:  Lu Yang; Wei Ji; Yanhong Xue; Liangyi Chen
Journal:  J Mol Med (Berl)       Date:  2013-05-23       Impact factor: 4.599

Review 2.  Defining and achieving treatment success in patients with type 2 diabetes mellitus.

Authors:  Mark W Stolar
Journal:  Mayo Clin Proc       Date:  2010-11-24       Impact factor: 7.616

3.  Prevalence of diabetes mellitus after extra corporeal shock wave lithotripsy in 15 years follow-up.

Authors:  Fahimeh Kazemi Rashed; Nader Rash Ahmadi; Ali Zolfaghari; Alireza Farshi; Mohsen Amjadi; Mahboobeh Gholipour
Journal:  Urol Ann       Date:  2017 Jul-Sep

4.  Thiazolidinediones and cardiovascular risk - a question of balance.

Authors:  Erland Erdmann; Bernard Charbonnel; Robert Wilcox
Journal:  Curr Cardiol Rev       Date:  2009-08

5.  Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise.

Authors:  K Stenlöf; W T Cefalu; K-A Kim; M Alba; K Usiskin; C Tong; W Canovatchel; G Meininger
Journal:  Diabetes Obes Metab       Date:  2013-01-24       Impact factor: 6.577

6.  Management of obesity, insulin resistance and type 2 diabetes in children: consensus and controversy.

Authors:  Amy Fleischman; Erinn T Rhodes
Journal:  Diabetes Metab Syndr Obes       Date:  2009-11-27       Impact factor: 3.168

7.  Impact of three oral antidiabetic drugs on markers of β-cell function in patients with type 2 diabetes: a meta-analysis.

Authors:  Jin Lu; Jiajie Zang; Huihua Li
Journal:  PLoS One       Date:  2013-10-25       Impact factor: 3.240

8.  Effects of semaglutide on beta cell function and glycaemic control in participants with type 2 diabetes: a randomised, double-blind, placebo-controlled trial.

Authors:  Christoph Kapitza; Kirsten Dahl; Jacob B Jacobsen; Mads B Axelsen; Anne Flint
Journal:  Diabetologia       Date:  2017-05-19       Impact factor: 10.122

9.  Stimulation of insulin secretion by large-dose oral arginine administration in healthy adults.

Authors:  Zhu-Qi Tang; Tao Wu; Shi-Wei Cui; Xiao-Hui Zhu; Tong Yin; Cui-Fang Wang; Jing-Yi Zhu; Ai-Juan Wu
Journal:  Exp Ther Med       Date:  2013-05-16       Impact factor: 2.447

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.